These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30762169)

  • 1. Choosing Wisely: five recommendations related to tests, treatments, and procedures at risk of inappropriateness in the cure of Parkinson's disease (LIMPE-DISMOV Academy).
    Avanzino L; Cortelli P;
    Neurol Sci; 2019 Aug; 40(8):1733-1735. PubMed ID: 30762169
    [No Abstract]   [Full Text] [Related]  

  • 2. Contralateral levodopa-induced hemichorea in a patient with severe asymmetric Parkinson's disease.
    Yoo SW; Kim JS
    Acta Neurol Belg; 2020 Jun; 120(3):691-693. PubMed ID: 30840221
    [No Abstract]   [Full Text] [Related]  

  • 3. Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: case report.
    Gambarin M; Antonini A; Moretto G; Bovi P; Romito S; Fiaschi A; Tinazzi M
    Mov Disord; 2006 Feb; 21(2):270-3. PubMed ID: 16161148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical criteria of Parkinson's disease].
    Ransmayr G
    Ther Umsch; 2007 Jan; 64(1):5-8. PubMed ID: 17221818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medication treatment for Parkinson's disease].
    Reichmann H
    Nervenarzt; 2005 Dec; 76(12):1547-57; quiz 1558. PubMed ID: 16283151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the behavioral aspects of Parkinson's disease.
    Borek LL; Chou KL; Friedman JH
    Expert Rev Neurother; 2007 Jun; 7(6):711-25. PubMed ID: 17563253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa for Parkinson's disease.
    Devos D; Moreau C; Destée A
    N Engl J Med; 2009 Feb; 360(9):935-6; author reply 936. PubMed ID: 19246370
    [No Abstract]   [Full Text] [Related]  

  • 9. Subacute dopa-responsive Parkinsonism after successful surgical treatment of aqueductal stenosis.
    Kinugawa K; Itti E; Lepeintre JF; Mari I; Czernecki V; Heran F; Clemenceau S; Vidailhet M; Roze E
    Mov Disord; 2009 Dec; 24(16):2438-40. PubMed ID: 19908324
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
    Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
    Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intervening in the neuropsychiatric features of Parkinson's disease.
    Weintraub D; Stern MB
    Expert Rev Neurother; 2007 Jun; 7(6):699-710. PubMed ID: 17563252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

  • 13. Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    Olanow CW; Stocchi F
    Eur J Neurol; 2000 May; 7 Suppl 1():3-8. PubMed ID: 11054152
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

  • 15. The initial treatment of Parkinson's disease.
    Factor SA
    Mov Disord; 2000 Mar; 15(2):360-1. PubMed ID: 10752599
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.
    Schillaci O; Pierantozzi M; Filippi L; Manni C; Brusa L; Danieli R; Bernardi G; Simonetti G; Stanzione P
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1452-6. PubMed ID: 16151764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinson's disease: a consensus meeting.
    Agid Y; Ahlskog E; Albanese A; Calne D; Chase T; De Yebenes J; Factor S; Fahn S; Gershanik O; Goetz C; Koller W; Kurth M; Lang A; Lees A; Lewitt P; Marsden D; Melamed E; Michel PP; Mizuno Y; Obeso J; Oertel W; Olanow W; Poewe W; Pollak P; Tolosa E
    Mov Disord; 1999 Nov; 14(6):911-3. PubMed ID: 10584663
    [No Abstract]   [Full Text] [Related]  

  • 19. [Optimisation of treatment of Parkinson's disease with levodopa].
    Białecka M; Adamiak U; Gawrońska-Szklarz B
    Neurol Neurochir Pol; 2009; 43(5):446-59. PubMed ID: 20054747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 Oct; 30(10):1009-10. PubMed ID: 27541606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.